Dimethyl sulfoxide, dexamethasone, and calcium were tested in combination for their enhancing effects on cytomegalovirus detection in shell vial cultures on 1,579 clinical specimens obtained primarily from adult solid-organ transplant recipients. Fluorescent-focus counts were elevated for the cytomegalovirus-positive urine specimens (P < 0.01) and throat washings (P < 0.05) but not for the tissue biopsy or blood samples. Epidermal growth factor also increased focus counts but provided no additional benefit when used in combination with the other agents. The triple-combination treatment did not increase the number of positive specimens identified.
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Detection of cytomegalovirus (CMV) in culture by the demonstration of CMV immediate-early antigen (IEA) enables much more rapid identification of CMV than standard tube culture (7, 17) . Additionally, in vitro infectivity of CMV is enhanced by centrifugation of the clinical specimen onto monolayers of human fibroblasts (8) . These two techniques in combination have been extensively investigated for clinical diagnostic use (5, 6, 9, 12, (18) (19) (20) . The sensitivity and specificity of centrifugation plus IEA detection (commonly called shell vial culture) for CMV are now considered close to and in some reports higher than those for standard tube culture.
More recently, chemical agents, including dimethyl sulfoxide (DMSO), dexamethasone (DXM), and calcium chloride (CaCl2), have been reported to further enhance the in vitro infectivity of CMV in shell vial culture (13, 15, (21) (22) (23) . Not all investigations, however, have demonstrated increased identification of CMV directly by treatment with these agents (3, 4) . Since in vitro adaptation of a virus can occur even with minimal passaging, we were interested in investigating the effects of these agents on the detection of CMV directly in clinical specimens. We also investigated the effects of epidermal growth factor (EGF), a commonly used in vitro mitogen (1, 14) , on enhancement of CMV isolation by the shell vial method because CMV is known to exhibit enhanced replication in actively replicating cells (2) .
Preliminary experiments to determine optimal concentrations of DMSO levels of enhancement were noted with all concentrations of DXM from i0-4 to 10-6 M (data not shown); 10-6 M DXM was therefore selected for use in all further studies. Enhancement with CaCl2 treatment was greatest at 5 mM, and EGF enhancement was greatest at 50 ng/ml (data not shown).
It has been reported that the enhancement effect of DXM in CMV shell vials is optimized when the vials are treated prior to inoculation as well as after inoculation of virus (13, 21, 22) . We confirmed that pretreatment of shell vials with DXM within 24 h of inoculation as well as the inclusion of DXM in the overlay after inoculation (posttreatment) resulted in a higher fluorescent-focus count than posttreatment inclusion of DXM alone (data not shown). However, while pretreatment with EGF 3 h prior to inoculation produced greater enhancement than EGF posttreatment alone, overnight pretreatment with EGF was inhibitory (Fig. 1) . This is consistent with findings for EGF and CMV in standard culture (11) . Since a 3-h pretreatment step is impractical in our diagnostic laboratory, EGF was used only postinoculation.
The agents were then tested individually and in combination on five low-passage (in vitro) clinical isolates of CMV. The isolates ranged from passage 3 to passage coverslip were counted under epifluorescence microscopy and averaged for each treatment.
For each virus, the percent change in fluorescent-focus count with each treatment compared with untreated controls was calculated, and then the average percent change was calculated for the five low-passage clinical isolates. When these agents were added in combination, the enhancing effect was greater than when they were used individually (Fig. 2) 12 stool samples, and 6 pleural fluid specimens. Of the 1,579 specimens, 133 were positive in shell vial culture for CMV. For 100 of the positive specimens, accurate counts of fluorescent foci in both treated and untreated vials were possible. In 62 of these specimens, focus counts were elevated in the treated vial compared with those in the untreated vial (P < 0.01, Wilcoxon signed-rank test), while counts for 33 specimens were decreased by the treatment and counts for 5 specimens were unchanged.
Positive specimens were then divided according to the type of specimen, and the effect of the agents was assessed for each (Table 1) , since the enhancing effect of these agents has been suggested to be dependent on specimen type (16) . Significant increases were seen in urine and throat wash specimens only.
While specimen numbers were too low for conclusions about the effects of these agents on bronchoalveolar lavage or sputum samples to be drawn, the agents did not appear to produce significant enhancement in CMV shell vial culture of tissue biopsy (P > 0.05) or buffy coat (P > 0.05) specimens.
We found no increase in the number of positive specimens when the enhancing agents were applied to clinical specimens, in contrast to other workers' findings (22, 23 (2) . Additionally, the mitogenic effects of DXM and CaCl2 have been related to enhanced detection of CMV in shell vial culture (23) . Likewise, we found that the addition of EGF, a fibroblast cell mitogen (1, 14) , also enhanced CMV detection in shell vial culture. While this effect was striking when EGF was applied in the absence of the other agents, no increase was observed beyond that already produced by treatment with the combination of DMSO, DXM, and CaC12. It is possible that some antagonism occurred between the calcium and EGF with regard to mitogenic stimulation (10) 
